Agilent Presents Thought Leader Award to Professor Jason Kovacic
10 Janvier 2022 - 02:18PM
Business Wire
Victor Chang Cardiac Research Institute (VCCRI) researcher
recognized for his influential work on cardiovascular disease
Agilent Technologies Inc. (NYSE: A) today announced that
Professor Jason Kovacic has been selected to receive a prestigious
Agilent Thought Leader Award. Professor Kovacic is being recognized
for his influential research on cardiovascular disease—specifically
the pathobiology of vascular diseases, coronary artery disease,
fibromuscular dysplasia and spontaneous coronary artery
dissection.
Professor Kovacic is the Executive Director of the Victor Chang
Cardiac Research Institute. He is also the Robert Graham Chair and
Professor of Medicine at the University of New South Wales, and a
Professor of Medicine at the Icahn School of Medicine at Mount
Sinai, New York.
Professor Kovacic’s research will generate important proteomics
and metabolomics data sets, using Agilent mass spec solutions, to
further integrate them to existing genomics data sets in animal and
human systems for the disease fibromuscular dysplasia. This complex
approach will be assisted with artificial intelligence and seeks to
convert data to knowledge, which may assist with translation to
clinical utility. In addition to his ongoing research to identify
the causes and treat vascular disease, Professor Kovacic is a
practicing clinical cardiologist specializing in vascular disease
and blockages of the heart arteries.
“It’s a great honor to be the recipient of this prestigious
Agilent Thought Leader Award,” said Prof. Kovacic. “I thank Agilent
for the recognition and look forward to continuing our work in
cardiovascular research at the Institute with Agilent’s strong
support and direct access to their cutting-edge scientific
instruments. I know this partnership will help propel our exciting
translational cardiovascular and heart disease research, as we work
to further understand these conditions that affect so many in
Australia and across the globe.”
“It’s a privilege to recognize Professor Kovacic for this award.
His research will enable insights into the causes of fibromuscular
dysplasia, potentially leading to tools for prediction and early
intervention,” said Sudharshana Seshadri, vice president and
general manager of Agilent’s Mass Spectrometry Division. “Agilent
strives to work with the best academic researchers worldwide to
support their work and identify new applications, tools, and
capabilities for our products—enabling novel clinical research and
analytical applications.”
The Agilent Thought Leader Award program promotes fundamental
scientific advances by contributing financial support, products,
and expertise to the research of influential thought leaders in the
life sciences, diagnostics, and chemical analysis space. The
continued investment in the segment markets Agilent serves provides
economic and societal impact and demonstrates its commitment to
improving the human condition.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in fiscal 2021 and employs 17,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005586/en/
Naomi Goumillout Agilent Technologies +1.781.266.2819
naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Agilent Technologies (NYSE:A)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024